Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellular Dynamics International (CDI) has published a research demonstrating the use of human iPSC-derived iCell Neurons to model Alzheimer's disease (AD) as well as its use in high throughput drug screening.
Subscribe to our email newsletter
CDI’s commercial iCell Neurons were used by GlaxoSmithKline (GSK) researchers to model neuronal loss in human AD brains by exposing them to beta-amyloid 1-42 (AB1-42), which grows in the brains of people susceptible to AD.
iCell Neurons is the first known human iPSCs to model Alzheimer’s disease through AB1-42 toxicity in a drug screen, according to CDI.
CDI chief operating officer Emile Nuwaysir said, "Prior to iCell Neurons, the research models available to study AD included mice, human postmortem tissues, and immortalized neuronal cell lines."
CDI chief executive officer Robert Palay said,"The work contained in this paper is just another example confirming that CDI’s ability to supply our customers with fully functional, standardized human cells enables pharmaceutical scientists to quickly discover new drug candidates, particularly for challenging pathologies such as neurodegenerative diseases.”